Frecuencia de las mutaciones en los genes BRCA en mujeres con agregación familiar de cáncer de glándula mamaria/ovario

作者: Jennyfer Dahianna Benavides-Cerquera , Mabel Elena Bohórquez-Lozano , Carlos Fernando Prada-Quiroga , Luis Carvajal-Carmona , María Magdalena Echeverry de Polanco

DOI: 10.15517/PSM.V14I1.25016

关键词: CancerFamily historyOvarian cancerPopulationGynecologyIncidence (epidemiology)Mammary glandGenotypingDiseaseMedicine

摘要: Objective: Collect evidence about the frequency variation of BRCA1 and BRCA2 mutations family history in patients with mammary gland cancer (MGC) ovarian (OC) from different geographical backgrounds. Method: This paper presents a systematic review using PRISMA protocol parameters to estimate prevalence BRCA 1/2 genes MGC OC, incidence observed sporadic cases this type cancer. Results: Heterogeneity is these studies ranging between 0.0 0.48 families OC similar those previously reported. Discussion: wide range due origin studied population, number individuals analyzed genotyping methodology used. The reveals that twice as common compared same disease origin. Conclusions: molecular allows other people who have perform early analysis tests prevent future development neoplasia.

参考文章(73)
Maya Ghoussaini, Paul D.P. Pharoah, Douglas F. Easton, Inherited genetic susceptibility to breast cancer: the beginning of the end or the end of the beginning? American Journal of Pathology. ,vol. 183, pp. 1038- 1051 ,(2013) , 10.1016/J.AJPATH.2013.07.003
Mauricio Tawil, Lilian Torregrosa, Ángela Umaña, Ignacio Briceño, Elías Quintero, Ute Hamman, José Joaquín Caicedo, José Fernando Robledo, Alejandro Orozco, Diana Torres, Estudio de factores genéticos para cáncer de mama en Colombia Universitas Médica. ,vol. 50, pp. 297- 301 ,(2009)
J. Abugattas, M. Llacuachaqui, Y. Sullcahuaman Allende, A. Arias Velásquez, R. Velarde, J. Cotrina, M. Garcés, M. León, G. Calderón, M. de la Cruz, P. Mora, R. Royer, J. Herzog, J.N. Weitzel, S.A. Narod, Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru. Clinical Genetics. ,vol. 88, pp. 371- 375 ,(2015) , 10.1111/CGE.12505
C M Schlebusch, G Dreyer, M D Sluiter, T M Yawitch, H J Van den Berg, E J Van Rensburg, Cancer prevalence in 129 breast-ovarian cancer families tested for BRCA1 and BRCA2 mutations South African Medical Journal. ,vol. 100, pp. 113- 117 ,(2010) , 10.7196/SAMJ.3235
Nadine Tung, Chiara Battelli, Brian Allen, Rajesh Kaldate, Satish Bhatnagar, Karla Bowles, Kirsten Timms, Judy E. Garber, Christina Herold, Leif Ellisen, Jill Krejdovsky, Kim DeLeonardis, Kristin Sedgwick, Kathleen Soltis, Benjamin Roa, Richard J. Wenstrup, Anne-Renee Hartman, Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next‐generation sequencing with a 25‐gene panel Cancer. ,vol. 121, pp. 25- 33 ,(2015) , 10.1002/CNCR.29010
Uziel Beller, David Halle, Raphael Catane, Bella Kaufman, Gila Hornreich, Ephrat Levy-Lahad, High frequency of BRCA1 and BRCA2 germline mutations in Ashkenazi Jewish ovarian cancer patients, regardless of family history Gynecologic Oncology. ,vol. 67, pp. 123- 126 ,(1997) , 10.1006/GYNO.1997.4844
Patricio Gonzalez-Hormazabal, Sara Gutierrez-Enriquez, Daniel Gaete, Jose M. Reyes, Octavio Peralta, Enrique Waugh, Fernando Gomez, Sonia Margarit, Teresa Bravo, Rafael Blanco, Orland Diez, Lilian Jara, Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families Breast Cancer Research and Treatment. ,vol. 126, pp. 705- 716 ,(2011) , 10.1007/S10549-010-1170-Y
Alexandra Ortiz Rodríguez, Marcia Llacuachaqui, Gonzalo Guevara Pardo, Robert Royer, Garrett Larson, Jeffrey N. Weitzel, Steven A. Narod, BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia Gynecologic Oncology. ,vol. 124, pp. 236- 243 ,(2012) , 10.1016/J.YGYNO.2011.10.027
Kirsi M Kuusisto, Aleksandra Bebel, Mauno Vihinen, Johanna Schleutker, Satu-Leena Sallinen, Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals Breast Cancer Research. ,vol. 13, pp. 1- 13 ,(2011) , 10.1186/BCR2832